Logo

Roche: Jörg Duschmalé, Patrick Frost

Mar 17, 2020

Roche has elected Jörg Duschmalé and Patrick Frost to its board of directors, while Andreas Oeri and John Bell have stepped down after 24 and 19 years on the board, respectively. Oeri was the representative of the current shareholder pool.

Duschmalé is a fifth-generation descendant of Roche's founder, and he was a postdoctoral researcher in oligonucleotide chemistry at Roche from 2015 to 2018. Frost has worked at life insurance company Swiss Life in Zurich since 2006, first as Group Chief Information Office and now as Group CEO. He previously served as the global head of fixed income investment at Winterthur Insurance.
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.